Diseases / Psoriasis
Psoriasis
DiseasePsoriasis is a chronic immune-mediated inflammatory skin disease marked by accelerated keratinocyte turnover and recurrent erythematous scaly plaques.
- Trials
- 1454
- Recruiting
- 121
- Completed
- 975
- With results
- 429
Last revised
Pipeline
Phase by status
| Phase | Recruiting | Not yet | By invitation | Active | Completed | Terminated | Withdrawn | Suspended | Unknown | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Early Phase 1 | 2 | — | 1 | — | 5 | 2 | 2 | — | 4 | 16 |
| Phase 1 | 9 | 2 | — | 3 | 123 | 12 | 2 | — | 7 | 158 |
| Phase 1/2 | — | — | — | 1 | 20 | 4 | — | — | 3 | 28 |
| Phase 2 | 10 | 3 | — | 2 | 203 | 19 | 6 | 3 | 9 | 255 |
| Phase 2/3 | 1 | 1 | — | — | 8 | 2 | — | — | 1 | 13 |
| Phase 3 | 9 | 5 | 1 | 5 | 204 | 12 | 6 | — | 9 | 251 |
| Phase 4 | 14 | 6 | — | 3 | 116 | 11 | 5 | — | 28 | 183 |
| Not applicable | 27 | 10 | — | 6 | 107 | 9 | 5 | — | 39 | 203 |
| Unknown | 49 | 20 | 5 | 19 | 189 | 14 | 8 | 2 | 41 | 347 |
Trials started per year
Conditions studied, by phase
| Condition | Early Phase 1 | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | Phase 4 | Not applicable | Unknown | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Psoriasis | 16 | 158 | 28 | 255 | 13 | 251 | 183 | 203 | 347 | 1454 |
| Arthritis, Psoriatic | 1 | 5 | 1 | 9 | 1 | 22 | 10 | 22 | 55 | 126 |
| Dermatitis, Atopic | 2 | 8 | 1 | 4 | — | 2 | 6 | 14 | 35 | 72 |
| Skin Diseases | 1 | 3 | 1 | 17 | — | 17 | 7 | 4 | 9 | 59 |
| Arthritis, Rheumatoid | 1 | 6 | 1 | 2 | — | — | 1 | 6 | 34 | 51 |
| Crohn Disease | — | 3 | — | 2 | — | — | 2 | 2 | 28 | 37 |
| Pruritus | — | 1 | — | 6 | — | 14 | 2 | 6 | 4 | 33 |
| Spondylitis, Ankylosing | 1 | — | 1 | 2 | — | — | — | 1 | 26 | 31 |
| Eczema | 1 | 2 | — | 5 | — | — | 1 | 9 | 12 | 30 |
| Inflammation | — | 3 | — | 5 | — | 5 | 1 | 3 | 11 | 28 |
Most active sponsors
| # | Sponsor | Trials | Phase 3 |
|---|---|---|---|
| 1 | Amgen | 50 | 24 |
| 2 | Novartis Pharmaceuticals | 49 | 24 |
| 3 | AbbVie | 44 | 20 |
| 4 | Pfizer | 39 | 9 |
| 5 | Bristol-Myers Squibb | 31 | 8 |
| 6 | Eli Lilly and Company | 23 | 10 |
| 7 | Boehringer Ingelheim | 20 | 4 |
| 8 | Bausch Health Americas, Inc. | 18 | 3 |
| 9 | Janssen Research & Development, LLC | 18 | 10 |
| 10 | Cairo University | 17 | 1 |
Most studied interventions
| # | Intervention | Trials |
|---|---|---|
| 1 | Etanercept | 66 |
| 2 | secukinumab | 63 |
| 3 | Adalimumab | 61 |
| 4 | Ustekinumab | 49 |
| 5 | apremilast | 46 |
| 6 | Methotrexate | 42 |
| 7 | guselkumab | 33 |
| 8 | risankizumab | 32 |
| 9 | deucravacitinib | 29 |
| 10 | calcipotriene | 27 |
Evidence
- Results reported
- 44%429 of 975 completed
- Published
- 9.7%95 of 975 completed
- Primary endpoint met
- 56.6%380 of 671 analyses
- Median months to report
- 17
Documents disclosed
Trial profile
- Median enrollment
- 84
- Median duration
- 21months
- Countries
- 76
- Study sites
- 14477
Who is enrolled
Median enrollment by phase
- Early Phase 1
- 13
- Phase 1
- 34
- Phase 1/2
- 19
- Phase 2
- 62
- Phase 2/3
- 125
- Phase 3
- 311
- Phase 4
- 50
- Not applicable
- 50
- Unknown
- 200
Where trials run
Busiest cities
| # | City | Country | Trials |
|---|---|---|---|
| 1 | New York | United States | 132 |
| 2 | Hamburg | Germany | 118 |
| 3 | Dallas | United States | 116 |
| 4 | Montreal | Canada | 114 |
| 5 | Houston | United States | 111 |
| 6 | Berlin | Germany | 109 |
| 7 | Portland | United States | 109 |
| 8 | San Diego | United States | 109 |
| 9 | Waterloo | Canada | 107 |
| 10 | San Antonio | United States | 104 |
Terminations
- Terminated
- 85
- Withdrawn
- 34
- Suspended
- 5
- Stopped for recruitment
- 2.1%31 of 1454 trials
Stated reasons
Reasons are grouped from the sponsor's own wording with a rule-based classifier; the original text is shown below.
Recently stopped
| Trial | Status | Stated reason | Stopped |
|---|---|---|---|
| NCT04031469 Suspended | Suspended | Administrative | 2030-12-10 |
| NCT04099979 Withdrawn | Withdrawn | Company focus shifted | 2030-07-31 |
| NCT06886009 Withdrawn | Withdrawn | Sponsor decision | 2029-06-08 |
| NCT07314060 Terminated | Terminated | Due to the company's strategic adjustment in product portfolio, this study has been voluntarily terminated. | 2026-07-30 |
| NCT07449234 Terminated | Terminated | Study terminated due to insufficient enrollment. | 2026-06-29 |
| NCT06723171 Suspended | Suspended | Sponsor request for study hold | 2026-04-30 |
| NCT05601492 Withdrawn | Withdrawn | Terminated IRB approval 6/26/2024, study was never initiated or activated | 2026-02-28 |
| NCT07000630 Terminated | Terminated | Terminated early due to lack of expected efficacy. Three participants were enrolled but none completed the study. | 2025-12-01 |
| NCT07255781 Withdrawn | Withdrawn | The sponsor determined that enrollment would not meet their expectations and decided to withdraw the study. | 2025-11-30 |
| NCT06242847 Terminated | Terminated | The study's collaborating dermatologist left the institution, and so skin biopsies could no longer be performed. | 2025-11-12 |
Trial records
Individual study records live on ClinicalTrials.gov. A sample of the trials counted above: